

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/790,996	03/02/2004	Paul O. Sheppard	01-18D1	3994	
10117 759	90 11/03/2006	EXAMINER			
ZYMOGENE	•	SEHARASEYON,	SEHARASEYON, JEGATHEESAN		
	AL PROPERTY DEPART KE AVENUE EAST	ART UNIT	PAPER NUMBER		
SEATTLE, WA	A 98102-3702		1647		
			DATE MAILED: 11/03/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		/	Application No.	Applicant(s)				
Office Action Summary			10/790,996	SHEPPARD ET AL.				
		T	Examiner	Art Unit				
	•		Jegatheesan Seharaseyon, Ph.D	1647				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR THE MANAGEMENT OF T	AILING DAT of 37 CFR 1.136(unication. tutory period will: will, by statute, ca	TE OF THIS COMMUNICATION a). In no event, however, may a reply be time apply and will expire SIX (6) MONTHS from the suse the application to become ABANDONEI	l. ely filed the mailing date of this commi D (35 U.S.C. § 133).				
Status								
1)🖂	Responsive to communication(s) file	d on <u>11 Aug</u>	ust 2006.					
2a)□	This action is FINAL . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)🛛	Claim(s) 1-23 is/are pending in the a	pplication.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.							
6)□	6) Claim(s) is/are rejected.							
•	Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-23</u> are subject to restriction	on and/or ele	ection requirement.					
Applicati	on Papers				•			
9)	The specification is objected to by the	Examiner.						
10)	The drawing(s) filed on is/are:	a) accep	ted or b) \square objected to by the E	xaminer.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	ınder 35 U.S.C. § 119							
12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
Awash								
Attachmen	t(s) e of References Cited (PTO-892)		4) Interview Summary	(PTO-413)				
2) Notic	e of Draftsperson's Patent Drawing Review (P	TO-948)	Paper No(s)/Mail Da	te				
	mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		5) Notice of Informal Page 6) Other:	atent Application				

Application/Control Number: 10/790,996

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-8 and 23, drawn to isolated polypeptide, classified in class 530, subclass 350.
 - II. Claims 9-21, drawn to a DNA sequence comprising a nucleotide sequence encoding a protein, a vector and host cell, classified in class 536, subclass 23.5.
 - III. Claim 22, drawn to an antibody or antibody fragment that binds to polypeptide, classified in class 530, subclass 387.1

The inventions are distinct, each from the other because of the following reasons:

Inventions I-III are directed to related products. The related inventions are a. distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, Groups I-III are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. For example, the protein of Group I can be prepared by processes which are materially different from recombinant DNA expression of Group II, such as by chemical synthesis, or by isolation and purification from natural sources. Additionally, the DNA of Group II can be used other than to make the protein of Group I, such as a probe in nucleic acid hybridization assays. The protein of Group I can be used in materially different methods other than to make the antibody of Group III, such as in the therapeutic or diagnostic methods (e.g., in screening). Although the antibody of Group III

Application/Control Number: 10/790,996

Art Unit: 1647

can be used to obtain the DNA of Group II, it can be used in materially different methods, such as in various diagnostic (e.g., as a probe in immunoassays or immunochromatography), or therapeutic methods. Furthermore, the distinct products require separate, distinct, and non-coextensive searches. As such, it would be burdensome to search the inventions of Groups I-III together.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different classification and different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

2. In addition, Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/790,996

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JS Art unit 1647 October 16, 2006

Gesatherson Schoraseryn Patent Examiner